Fernández-de-Las-Peñas César, Herrero-Montes Manuel, Ferrer-Pargada Diego, Izquierdo-Cuervo Sheila, Arendt-Nielsen Lars, Nijs Jo, Parás-Bravo Paula
Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.
CNAP, Center for Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.
J Clin Med. 2022 Jun 18;11(12):3512. doi: 10.3390/jcm11123512.
Individuals who survived coronavirus disease, 2019 (COVID-19), often have symptoms of sensitization, but the extent to which these symptoms relate to serological biomarkers remains unclear. Therefore, this secondary analysis evaluated the association between serological biomarkers at hospital admission with sensitization-associated post-COVID-19 symptoms in a sample of previously hospitalized COVID-19 survivors. Sixty-seven individuals hospitalized due to SARS-CoV-2 infection in one urban hospital of Madrid (Spain) during the first wave of the pandemic were assessed a mean of 6.0 (SD 0.8) months after hospital discharge. The Central Sensitization Inventory (CSI) was used as rough tool to estimate the presence of sensitization-associated post-COVID-19 symptoms (≥40/100 points). Levels of 16 serological biomarkers collected at hospital admission were obtained from medical records. Twenty-four (35.8%) patients reported sensitization-associated post-COVID-19 symptoms (CSI ≥ 40 points). Subjects reporting sensitization-associated symptoms had lower ferritin and hemoglobin levels than those not reporting sensitization-associated post-COVID-19 symptoms; however, these differences were small. We observed significant but small negative associations of the CSI score with ferritin (r: -0.251, = 0.04) and hemoglobin (r: -0.292, = 0.017) levels. No other significant difference was found. In conclusion, this secondary analysis did not find significant associations between the investigated serological biomarkers at hospital admission and sensitization-associated post-COVID-19 symptoms at 6 months after hospitalization in COVID-19 survivors.
2019年冠状病毒病（COVID-19）康复者常常出现过敏症状，但这些症状与血清生物标志物之间的关联程度尚不清楚。因此，本项二次分析评估了一组曾住院的COVID-19康复者入院时血清生物标志物与COVID-19后过敏相关症状之间的关联。在西班牙马德里一家城市医院，对第一波疫情期间因感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）而住院的67名患者进行了评估，评估时间为出院后平均6.0（标准差0.8）个月。采用中枢致敏量表（CSI）作为粗略工具来评估是否存在与过敏相关的COVID-19后症状（≥40/100分）。从病历中获取入院时采集的16种血清生物标志物水平。24名（35.8%）患者报告了与过敏相关的COVID-19后症状（CSI≥40分）。报告有过敏相关症状的受试者的铁蛋白和血红蛋白水平低于未报告有COVID-19后过敏相关症状的受试者；然而，这些差异很小。我们观察到CSI评分与铁蛋白（r：-0.251，P = 0.04）和血红蛋白（r：-0.292，P = 0.017）水平之间存在显著但较小的负相关。未发现其他显著差异。总之，本项二次分析未发现COVID-19康复者入院时所研究的血清生物标志物与住院6个月后与过敏相关的COVID-19后症状之间存在显著关联。
